Ethyl 4-[4-(3-cyano-2-pyridinyl)piperazin-1-yl]-1-(3,4-difluorophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate
C25H21F2N7O2 — CID 162658782
Data last refreshed: (MolForge compound catalog, from PubChem)
About Ethyl 4-[4-(3-cyano-2-pyridinyl)piperazin-1-yl]-1-(3,4-difluorophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate
Ethyl 4-[4-(3-cyano-2-pyridinyl)piperazin-1-yl]-1-(3,4-difluorophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate (PubChem CID 162658782) has the molecular formula C25H21F2N7O2 and a molecular weight of 489.49 g/mol. Its IUPAC name is ethyl 4-[4-(3-cyano-2-pyridinyl)piperazin-1-yl]-1-(3,4-difluorophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate.
Molecular Properties
| Compound Name | Ethyl 4-[4-(3-cyano-2-pyridinyl)piperazin-1-yl]-1-(3,4-difluorophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate |
|---|---|
| PubChem CID | 162658782 |
| Molecular Formula | C25H21F2N7O2 |
| Molecular Weight | 489.49 g/mol |
| Exact Mass | 489.17 |
| IUPAC Name | ethyl 4-[4-(3-cyano-2-pyridinyl)piperazin-1-yl]-1-(3,4-difluorophenyl)pyrazolo[3,4-b]pyridine-5-carboxylate |
| SMILES | CCOC(=O)c1cnc2c(cnn2-c2ccc(F)c(F)c2)c1N1CCN(c2ncccc2C#N)CC1 |
| InChI | InChI=1S/C25H21F2N7O2/c1-2-36-25(35)19-14-30-24-18(15-31-34(24)17-5-6-20(26)21(27)12-17)22(19)32-8-10-33(11-9-32)23-16(13-28)4-3-7-29-23/h3-7,12,14-15H,2,8-11H2,1H3 |
| InChIKey | GGMQTLJQVBDPQO-UHFFFAOYSA-N |
| XLogP | 3.47 |
| TPSA | 100.17 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 489.49 |
| LogP ≤ 5 | 3.47 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 162658782 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.